Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018

世界の慢性閉塞性肺疾患(COPD)治療市場:薬物治療、酸素治療、手術、肺リハビリテーション、生活習慣

◆タイトル:Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018
◆商品コード:IRTNTR4201
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年10月1日
◆ページ数:79
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥310,800見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥388,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"世界の慢性閉塞性肺疾患(COPD)治療市場:薬物治療、酸素治療、手術、肺リハビリテーション、生活習慣"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、種類別分析、主要地域別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About COPD
COPD is a broad term that covers various progressive lung diseases including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It is a serious condition that restricts airflow in the lungs and is characterized by increasing breathlessness. The exact etiology of COPD is not understood; however, most cases of COPD are caused due to genetic factors and by inhaling pollutants, including fumes and chemicals. The disease cannot be cured; it can be only be managed and treated.

TechNavio’s analysts forecast the Global COPD market to grow at a CAGR of 5.69 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global COPD market for the period 2014–2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs in the form of oral medications as well as inhalers for the treatment of COPD. The Global COPD market can be segmented into five: Medications, Oxygen Therapy, Surgery, Pulmonary Rehabilitation, and Lifestyle Changes.

TechNavio’s report, the Global COPD Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global COPD market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions
• Americas
• APAC
• EMEA

Key Vendors
• Astra Zeneca
• Boehringer Ingelheim
• GlaxoSmithKline
• Novartis
• Pfizer

Other Prominent VendorsAlere
• Almirall
• Astellas Pharma
• Axis Shield
• Beckton Dckinson
• Biosensors International
• Dainippon Sumitomo Pharma
• Medtronic
• Merck
• Mylan
• Novartis
• Siemens Healthcare Diagnostics
• Takeda Pharmaceutical
• Theravance

Market Driver
• Elderly Population
• For a full, detailed list, view our report

Market Challenge
• High Cost of COPD Treatment
• For a full, detailed list, view our report

Market Trend
• Increase in Awareness of COPD
• For a full, detailed list, view our report

Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01.Executive Summary
02.List of Abbreviations
03.Scope of the Report
03.1Market Overview
03.2Product Offerings
04.Market Research Methodology
04.1Market Research Process
04.2Research Methodology
05.Introduction
06.Market Landscape
06.1Market Overview
06.2Market Size and Forecast
07.Management of COPD
07.1Five Forces Analysis
08.Market Segmentation by Type of Treatment
09.Geographical Segmentation
09.1COPD Market in Americas
09.1.1Market Size and Forecast
09.2COPD Market in the EMEA Region
09.2.1Market Size and Forecast
09.3COPD Market in the APAC Region
09.3.1Market Size and Forecast
10.Buying Criteria
11.Rate of Incidence and Prevalence
11.1.1US
11.1.2Europe
11.1.3Asia
12.Pipeline Snapshot
13.Market Growth Drivers
14.Drivers and their Impact
15.Market Challenges
16.Impact of Drivers and Challenges
17.Market Trends
18.Trends and their Impact
19.Vendor Landscape
19.1Competitive Scenario
19.1.1Key News
19.1.2Mergers and Acquisitions
19.2Market Share Analysis 2013
19.3Other Prominent Vendors
20.Key Vendor Analysis
20.1AstraZeneca plc
20.1.1Key Facts
20.1.2Business Description
20.1.3Business Segmentation
20.1.4Business Strategy
20.1.5Revenue by Business Segmentation
20.1.6Revenue Comparison 2011-2013
20.1.7Sales Revenue by Geographical Segmentation
20.1.8Key Developments
20.1.9SWOT Analysis
20.2Boehringer Ingelheim
20.2.1Key Facts
20.2.2Business Overview
20.2.3Business Segmentation by Revenue 2013
20.2.4Business Segmentation by Revenue 2012 and 2013
20.2.5Geographical Segmentation by Revenue 2013
20.2.6Business Strategy
20.2.7Recent Developments
20.2.8SWOT Analysis
20.3GlaxoSmithKline plc
20.3.1Key Facts
20.3.2Business Overview
20.3.3Business Segmentation
20.3.4Business Segmentation by Revenue 2012 and 2013
20.3.5Sales by Geography
20.3.6Pipeline Products
20.3.7Business Strategy
20.3.8Key Information
20.3.9SWOT Analysis
20.4Pfizer Inc.
20.4.1Key Facts
20.4.2Business Description
20.4.3Business Segmentation
20.4.4Revenue by Business Segmentation
20.4.5Revenue Comparison 2012 and 2013
20.4.6Sales by Geography
20.4.7Business Strategy
20.4.8Key Developments
20.5SWOT Analysis
21.Other Reports in this Series

List of Exhibits
Exhibit 1:Market Research Methodology
Exhibit 2:Global COPD Market 2013-2018 (US$ billion)
Exhibit 3:Global COPD Market Segmentation by Type of Treatment
Exhibit 4:Global COPD Market Segmentation by Drug Class
Exhibit 5:Global COPD Market Segmentation by Drug Class 2013
Exhibit 6:Global COPD Market by Geographical Segmentation 2013
Exhibit 7:COPD Market in Americas 2013-2018 (US$ billion)
Exhibit 8:COPD Market in the EMEA Region
Exhibit 9:COPD Market in the APAC Region
Exhibit 10:Global COPD Market by Geographical Segmentation 2013-2018 (in percent)
Exhibit 11:Global COPD Market by Geographical Segmentation 2013-2018 (in revenue)
Exhibit 12:AstraZeneca plc: Business Segmentation
Exhibit 13:AstraZeneca plc: Revenue by Business Segmentation2013
Exhibit 14:AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 15:AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
Exhibit 16:Boehringer Ingelheim: Business Segmentation by Revenue 2013
Exhibit 17:Boehringer Ingelheim: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 18:Boehringer Ingelheim: Geographical Segmentation by Revenue 2013
Exhibit 19:GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 20:GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 21:GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 22:GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 23:Pfizer Inc.: Business Segmentation
Exhibit 24:Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 25:Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 26:Pfizer Inc.: Revenue by Geography 2013



【掲載企業】

Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer , Alere , Almirall , Astellas Pharma , Axis Shield, Beckton Dckinson , Biosensors International , Dainippon Sumitomo Pharma , Medtronic , Merck, Mylan, Novartis, Siemens Healthcare Diagnostics , TakedaPharmaceutical, Theravance

【資料のキーワード】

慢性閉塞性肺疾患(COPD)治療、医薬品、製薬、吸入器、薬物治療、酸素治療、手術、肺リハビリテーション、生活習慣

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[世界の慢性閉塞性肺疾患(COPD)治療市場:薬物治療、酸素治療、手術、肺リハビリテーション、生活習慣] (Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018 / IRTNTR4201)販売に関する免責事項
[世界の慢性閉塞性肺疾患(COPD)治療市場:薬物治療、酸素治療、手術、肺リハビリテーション、生活習慣] (Global Chronic Obstructive Pulmonary Disease (COPD) Market 2014-2018 / IRTNTR4201)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆